Monitoring the safety of quadrivalent human papillomavirus vaccine: Findings from the Vaccine Safety Datalink☆
Highlights
► We performed a post-licensure safety assessment of HPV4 among 9–26 year old female vaccine recipients between 2006 and 2009. ► Weekly sequential analyses conducted to detect associations between HPV4 exposure and pre-specified outcomes. ► No statistically significant increased risk detected for the outcomes studied. ► A non-significant RR of 1.98 for venous thromboembolism detected, further study needed.
Introduction
In June 2006, the Food and Drug Administration (FDA) licensed the quadrivalent human papillomavirus (HPV) vaccine (Gardasil®; Merck & Co. Inc., Whitehouse Station, New Jersey) for females aged 9–26 years. Gardasil®, or HPV4, is a virus-like particle vaccine composed of the major L1 capsid protein for HPV types 6, 11, 16, and 18 and an aluminum-containing adjuvant. The vaccine, administered in a series of three doses, is recommended by the Advisory Committee on Immunization Practices (ACIP) for routine use among females ages 11–12 years, permitted for girls as young as nine years of age, and recommended for females 13–26 years of age not previously vaccinated [1]. Prelicensure clinical trials have shown no evidence for any major safety problems [2], [3]. However, prelicensure studies were not adequately powered to detect rare adverse events. Because of this limitation, post-licensure monitoring of HPV4 safety using large population-based cohorts is needed.
The Vaccine Safety Datalink (VSD) is a collaboration of managed care organizations (MCOs) in the United States which collects medical information on more than 9 million people each year [4]. The VSD has developed a near real-time surveillance system, called Rapid Cycle Analysis (RCA), to monitor potential adverse events following licensure of new vaccines [5]. The purpose of this study was to determine whether HPV4 is associated with an increased risk of pre-specified clinically well-defined and severe adverse events in a large, nationally representative population.
Section snippets
Design and study population
Seven VSD sites, including Group Health Cooperative (Seattle, WA), Harvard Pilgrim Health Care and Harvard Vanguard Medical Associates (Boston, MA), HealthPartners Research Foundation (Minneapolis, MN), Kaiser Permanente of Colorado (Denver, CO), Kaiser Permanente of Northern California (Oakland, CA), Marshfield Clinic (Marshfield, WI) and Kaiser Permanente Northwest (Portland, OR) participated in this prospective cohort study. Females aged 9–26 years, identified at the participating sites from
Results
Monitoring of HPV4 occurred for 164 weeks during which a total of 600,558 doses were administered in the VSD population. 416,942 doses were administered to youth and 183,616 doses to adults.
Discussion
With over 600,000 doses administered, this is the largest population-based, post-licensure study of HPV4 safety in the United States. We confirmed no statistically significant increased risk between HPV4 and Guillain–Barré Syndrome (GBS), stroke, venous thromboembolism (VTE), appendicitis, anaphylaxis, seizure, syncope, or allergic reaction. While we did not confirm any statistically significant signals, an elevated RR of 1.98 for VTE among the youth was observed when the upper limit was
Acknowledgements
This study was supported through the Vaccine Safety Surveillance and Assessment Projects contract (200-2002-00732) with America's Health Insurance Plans, funded by the Centers for Disease Control and Prevention. We thank Lauri Markowitz MD, Barbara Slade MD, Jerry Tokars MD, MPH and Claudia Vellozzi MD, MPH for their technical guidance and editorial assistance. We acknowledge the excellent work of the Vaccine Safety Datalink team who provided data management, programming, medical record review
References (31)
- et al.
Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data
Vaccine
(2007) - et al.
Guillain–Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data
Vaccine
(2011) - et al.
Safety of human papillomavirus (HPV) vaccines: A review of the international experience so far
Vaccine
(2009) - et al.
Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP). Quadrivalent Human Papillomavirus Vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP)
MMWR Recomm Rep
(2007) Effect of prophylactic human paillomavirus L1 virus-like particle vaccine on the risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomized clinical trials
Lancet
(2007)- et al.
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
New Engl J Med
(2007) - et al.
Measles–mumps–rubella–varicella combination vaccine and the risk of febrile seizures
Pediatrics
(2010) - et al.
Vaccine safety datalink rapid cycle analysis team. Real-time vaccine safety surveillance for the early detection of adverse events
Med Care
(2007) - et al.
Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine
JAMA
(2009) - et al.
Risk of anaphylaxis after vaccination of children and adolescents
Pediatrics
(2003)
Trends in the incidence of deep vein thrombosis and pulmonary embolism. A 25-year population-based study
Arch Intern Med
The Worcester venous thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism
J Gen Intern Med
A Maximized Sequential Probability Ratio Test for Drug and Vaccine Safety Surveillance
Sequential Anal
Cited by (200)
Incidence of Adolescent Syncope and Related Injuries Following Vaccination and Routine Venipuncture
2024, Journal of Adolescent HealthAdverse events from HPV vaccination in Taiwan
2023, VaccineThrombosis and thrombocytopenia after HPV vaccination
2022, Journal of Thrombosis and Haemostasis
- ☆
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention nor that of America's Health Insurance Plans.